Antimicrobial susceptibility of Brucella melitensis isolates in Peru

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1279-1281

  Maves, Ryan C ^a,h   Castillo, Rosa ^a   Guillen, Alfredo ^b   Espinosa, Benjamin ^c   Meza, Rina ^a   Espinoza, Nereyda ^a   Núñez, Gladys ^a   Sánchez, Luis ^e   Chacaltana, Jesús ^d   Cepeda, David ^a   González, Sofía ^f   Hall, Eric R ^g  

^a Peru   (Peru)

^b Clinica San Borja   (Peru)

^c Navy Environ Prev Med U No 2   (United States)

^d HOSPITAL NACIONAL DANIEL ALCIDES CARRIÓN   (Peru)

^e HOSPITAL NACIONAL ARZOBISPO LOAYZA   (Peru)

^f Centro Médico Naval cirujano Mayor   (Peru)

^g NAVAL MEDICAL RESEARCH CENTER   (United States)

^h NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BRUCELLA MELITENSIS; BRUCELLOSIS; CLINICAL ARTICLE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERU; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BRUCELLA MELITENSIS; BRUCELLOSIS; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PERU; RIFAMPIN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 79952339973     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00979-10     Document Type: Article

References (15)

1. Aliskan, H., T. Turunc, Y. Z. Demiroglu, S. Colakoglu, and H. Arslan. 2008. Investigation of in vitro antibiotic susceptibility of Brucella melitensis. Mikrobiyol. Bul. 42:125-129.
2. Ariza, J., et al. 2007. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 4:e317.
3. Castaneda, M. R. 1947. A practical method for routine blood cultures in brucellosis. Proc. Soc. Exp. Biol. Med. 64:114.
4. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, vol. 29; 19th international supplement. M100-S19-MIC. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Dimitrov, T., D. Panigrahi, M. Emara, F. Awni, and R. Passadilla. 2004. Seroepidemiological and microbiological study of brucellosis in Kuwait. Med. Princ. Pract. 13:215-219.
6. Espinosa, B. J., et al. 2009. Comparison of culture techniques at different stages of brucellosis. Am. J. Trop. Med. Hyg. 80:625-627.
7. Etemadi, H., A. Raissadat, M. J. Pickett, Y. Zafari, and P. Vahedifar. 1984. Isolation of Brucella spp. from clinical specimens. J. Clin. Microbiol. 20:586.
8. Falagas, M. E., and I. A. Bliziotis. 2006. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob. Agents Chemother. 50:22-33.
9. Lopez-Merino, A., et al. 2004. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect. Dis. 36:636-638.
10. Mendoza-Nunez, M., et al. 2008. Brucellosis in household members of Brucella patients residing in a large urban setting in Peru. Am. J. Trop. Med. Hyg. 78:595-598.
11. Nockler, K., et al. 2009. Molecular epidemiology of Brucella genotypes in patients at a major hospital in central Peru. J. Clin. Microbiol. 47:3147-3155.
12. Pappas, G., N. Akritidis, M. Bosilkovski, and E. Tsianos. 2005. Brucellosis. N. Engl. J. Med. 352:2325-2336.
13. Smits, H. L., et al. 2009. MLVA genotyping of human Brucella isolates from Peru. Trans. R. Soc. Trop. Med. Hyg. 103:399-402.
14. Solera, J., J. L. Beato, E. Martinez-Alfaro, J. C. Segura, and E. de Tomas. 2001. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin. Infect. Dis. 32:506-509.
15. Tanyel, E., et al. 2007. Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region. Saudi Med. J. 28:1239-1242.